Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Gross Profit (2016 - 2025)

Cytosorbents' Gross Profit history spans 15 years, with the latest figure at $6.8 million for Q4 2025.

  • Quarterly results put Gross Profit at $6.8 million for Q4 2025, up 8.78% from a year ago — trailing twelve months through Dec 2025 was $26.5 million (up 6.44% YoY), and the annual figure for FY2025 was $26.5 million, up 6.45%.
  • Gross Profit for Q4 2025 was $6.8 million at Cytosorbents, up from $6.7 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $9.3 million in Q2 2021 to a low of $3.6 million in Q3 2022.
  • The 5-year median for Gross Profit is $6.3 million (2022), against an average of $6.3 million.
  • The sharpest move saw Gross Profit plummeted 50.43% in 2022, then soared 55.0% in 2023.
  • Year by year, Gross Profit stood at $7.7 million in 2021, then decreased by 24.84% to $5.8 million in 2022, then decreased by 7.74% to $5.3 million in 2023, then increased by 17.77% to $6.3 million in 2024, then rose by 8.78% to $6.8 million in 2025.
  • According to Business Quant data, Gross Profit over the past three periods came in at $6.8 million, $6.7 million, and $6.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.